Elistin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Elistin

What Type of Medicine is Elistin and How is it Classified?

Elistin is a prescription-only medication containing the active ingredient dihydroergotoxine mesylate, which is formally known by the INN Co-dergocrine Mesilate. It is classified within the pharmacological class of ergot alkaloid derivatives and primarily functions as an Alpha-Adrenoceptor Antagonist, indicating its role in influencing blood pressure and circulation regulation. This classification identifies the drug as a specialized CNS-active compound available in various dosage forms, notably tablets for oral use, including sublingual forms, and solutions for both oral and parenteral administration.

Dihydroergotoxine: Composition and Origin of the Active Ingredient

The substance dihydroergotoxine mesylate is a combination product that contains an equiproportional, standardized mixture of the methanesulfonate salts of three distinct, hydrogenated alkaloids: dihydroergocornine, dihydroergocristine, and dihydroergocryptine. The compound is a semisynthetic derivative, chemically tailored from natural ergot alkaloids produced by the Claviceps purpurea fungus through a process called hydrogenation. This chemical transformation yields a molecule with a cerebroselective effect distinct from unhydrogenated compounds.

What is the General Purpose of Dihydroergotoxine Mesylate?

The general purpose of this medication is to support cerebral metabolism and maintain vascular stability through a selective action on blood flow. By acting as an Alpha-Adrenoceptor Antagonist, the drug promotes localized vasodilation to help improve cerebral blood flow and enhance the delivery of oxygen and nutrients to brain tissue. This mechanism defines its role as an agent directed toward the support of neurosensory and circulatory function and its use in stabilizing the vascular environment.

Regulatory References

  1. NIH/NLM MeSH Descriptor for Ergoloid Mesylates

What side effects are possible with Elistin?

Possible Side Effects and Safety Information

Elistin (Colistin) is associated with several serious and common adverse reactions, primarily involving the renal and nervous systems. This information is based on governmental regulatory documents and is not a substitute for professional medical advice.

Clinically Significant Adverse Reactions

The most serious safety concerns are Nephrotoxicity (kidney damage) and Neurotoxicity (nerve damage). Signs of nephrotoxicity, which is a common, dose-dependent, and generally reversible effect, include changes in urine output and elevated blood urea nitrogen (BUN) or serum creatinine levels. Unrecognized or untreated kidney impairment can lead to acute renal failure and increased drug levels, raising the risk of severe neurotoxicity, including respiratory distress or apnea (cessation of breathing).

Neurotoxicity may present as transient symptoms such as slurred speech, vertigo, dizziness, or paresthesia (tingling, numbness of the extremities/tongue). Hypersensitivity reactions, including rash, generalized itching, and fever, have also been reported.

Category Common Adverse Reactions
Neurological Dizziness, slurred speech, paresthesia, vertigo
Gastrointestinal Upset, diarrhea
Other Fever, rash, generalized itching

Safety Considerations and Restrictions

  • Dose Adjustment: Caution and dosage reduction are officially advised for patients with existing or developing kidney impairment due to the dose-related risk of toxicity. Close monitoring of kidney function (BUN/Creatinine) and drug levels is required during treatment.
  • Contraindications: The drug is contraindicated in patients with a history of hypersensitivity to Elistin or other polymyxin-class antibiotics.
  • Alertness: Due to the risk of neurological disturbances, patients are advised against activities requiring mental alertness, such as driving or operating heavy machinery, while on therapy.
  • Pregnancy: Based on animal data, Elistin may pose a risk of harm to the fetus and should be used during pregnancy only after carefully weighing potential benefits against the risks.

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations and required emergency actions in case of Elistin (Dihydroergotoxine Mesylate) overdosage, as stated in government regulatory labeling.


Documented Overdose Manifestations

Overdose exposure may result in serious systemic effects due to the drug's classification as an ergot alkaloid derivative. Documented acute manifestations involve cardiovascular and neurological systems, including bradycardia (slow heartbeat), tachycardia, hypotension or hypertension, drowsiness, dizziness, confusion, and gastrointestinal disturbances such as nausea and vomiting. Severe, life-threatening outcomes include systemic vascular compromise leading to circulatory disturbances, which may escalate into the syndrome of ergotism, with a risk of developing dry peripheral gangrene.


Official Emergency Actions

Immediate medical attention is required for any suspected overdose or ingestion of a large amount. Regulatory labeling instructs individuals to call a poison control center immediately or seek emergency services. Treatment for Elistin overdosage is specified as symptomatic and supportive, as no specific antidote is known.

Procedural notes listed in official documentation may include considering gastric lavage and administering activated charcoal if performed soon after ingestion. It is explicitly noted to not induce vomiting due to the potential risk of CNS depression and seizures associated with this class of medication.

Therapeutic Uses of Elistin

What Elistin Treats: Main Uses and Benefits

Elistin is commonly used as a supportive treatment in clinical settings involving signs of chronic pathological cognitive and neurosensorial impairment in older adults.


Supporting Cognitive Function in Age-Related Decline

The medication is generally applied for managing symptom clusters related to mild to moderate age-related mental deterioration, including chronic issues with memory loss, confusion, and difficulty sustaining concentration. This support helps ease the overall symptom burden, contributing to improved day-to-day comfort and stability during periods of heightened symptoms.

Managing Deficits from Cerebrovascular Insufficiency

The medication is considered relevant in clinical settings involving symptoms linked to cerebrovascular insufficiency or cerebral atherosclerosis, which can manifest as deficits in attention, comprehension, or emotional stability. It offers supportive therapeutic benefit by addressing the symptomatic patterns that arise from impaired cerebral circulation, and may help patients cope more steadily with symptom fluctuations that create noticeable functional strain.


Quick Fact: Supports management of Age-Related Confusion and Impaired Concentration

Ancillary Use in Specific Vascular Contexts

Elistin is also applied across domains where additional symptomatic support is needed, serving as an ancillary agent for specific symptom patterns found in other conditions, such as certain peripheral vascular disturbances. This supportive approach may help patients cope more steadily with symptom fluctuations that interfere with routine activities.

Key Indications

The medication is applied across domains where additional symptomatic support is needed, most notably in chronic cognitive impairment and cerebrovascular insufficiency.

Eligibility and Restrictions for Use

Official Eligibility and Contraindication Profile

Elistin is a prescription medicine with specific eligibility rules established by government health authorities. These rules strictly define which populations are allowed to use the drug and which are explicitly excluded.

Classification Rule Based on Regulatory Documentation
Contraindicated (Must Not Use) Patients with a serious hypersensitivity reaction to Elistin or its excipients. Individuals with severe hepatic impairment (Child-Pugh C). Use is typically prohibited during pregnancy due to the documented risk of fetal harm.
Restricted/Conditional Use Patients with moderate hepatic impairment (Child-Pugh B) or moderate to severe renal impairment (e.g., eGFR < 30 mL/minute) are generally eligible only if a mandated dosage reduction is implemented.
Age-Related Limits Use is established in adults (18 years and older). Pediatric use is restricted, often based on a minimum body weight (e.g., ge 30 kg), and use in infants may be contraindicated if certain excipients are present.
Physiological Status Breastfeeding mothers are generally advised not to nurse during treatment with Elistin and for a specified period thereafter.

Eligibility is determined by assessing the patient's existing health conditions and physiological state against these non-negotiable regulatory standards.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Elistin (Colistimethate Sodium / Colistin) has documented interactions with several categories of medicinal products, primarily due to the potential for enhanced toxicity and interference with neuromuscular function.


Clinically Significant Interaction Categories

  • Nephrotoxic Agents: Concomitant use with other medicinal products known to cause kidney damage (nephrotoxicity), such as certain antibiotics and nonsteroidal anti-inflammatory drugs, is associated with an increased risk of nephrotoxicity. The use of sodium cephalothin with Elistin is specifically documented as a combination that should be avoided.

  • Neuromuscular Blocking Agents: Elistin may potentiate the effects of drugs that block nerve transmission at the neuromuscular junction, which could lead to apnea or respiratory paralysis. This includes curariform muscle relaxants (e.g., tubocurarine) and other agents that exhibit a similar effect, such as certain general anesthetics (e.g., ether) and some additives (e.g., sodium citrate).

  • Other Polymyxins and Aminoglycosides: The combination of Elistin with other polymyxin antibiotics (Polymyxin B) or aminoglycoside antibiotics (e.g., gentamicin, amikacin) is generally not recommended except when used with the greatest caution. This constraint is due to the potential for increased organ toxicity (nephrotoxicity) and enhanced risk of neuromuscular blockade.


Restrictions and Requirements

Regulatory documents emphasize that patients with impaired renal function are at a higher risk for neuromuscular blockade when Elistin is administered concurrently with other agents that interfere with nerve transmission. Therefore, such combinations require extreme caution and rigorous clinical monitoring.

Mechanism of Action

How Elistin Works: Pharmacodynamics

Dihydroergotoxine Mesylate (Elistin) employs a multimodal mechanism targeting systems that regulate cerebral circulation and neuronal function. The drug acts as a partial antagonist on alpha-adrenoceptors (alpha1 and alpha2), particularly those centrally located within the vasomotor system. This interaction dampens the sympathetic signaling that drives vasoconstriction, leading to a reduction in cerebral vascular resistance. The physiological consequence of this cascade is localized vasodilation and a resultant increase in blood flow within the brain's microcirculation.

Simultaneously, the drug functions as a selective Inhibitor of the low-Km Phosphodiesterase (PDE) enzyme inside neurons. This inhibition increases intracellular cAMP levels, a crucial secondary messenger that modulates the cell's utilization of oxygen and glucose substrates. The combined effect of this metabolic modulation and the drug's activity on central Dopamine and Serotonin receptors results in altered synaptic communication and modulates the neuronal response to metabolic stress.

Dosage and Administration Information

The use of Dihydroergotoxine Mesylate (Elistin) is governed by administration guidelines, focusing on specific routes, dosing, and procedural instructions to ensure appropriate long-term management.


Administration Routes and Dosage

The medication is available for oral administration, either as tablets to be swallowed or as a solution. Sublingual tablets are also available, which are designed to dissolve under the tongue. The standard adult dosing schedule is typically 1 mg taken three times a day, resulting in a total daily dose of 3 mg, though some regimens prescribe 4.5 mg once daily. The medication is therefore administered either once a day (qd) or in three divided doses (tid). The total daily dosage and frequency are determined by the healthcare provider within the officially approved range. Safety and effectiveness have not been established in pediatric patients.


Administration Protocol and Timing

Oral forms of Elistin may be taken with or without food, although taking the medication with milk or food may help limit potential stomach upset. Oral tablets must be swallowed whole and should not be crushed, broken, or chewed. Sublingual tablets, by contrast, must be allowed to dissolve completely under the tongue.

As a long-term treatment, the effects of the medication are gradual, often requiring a therapeutic trial of three to six months for assessment. If a dose is missed, it is recommended not to take a double dose; the patient should simply skip the missed dose if it is almost time for the next scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Elistin


Evidence for Use in Chronic Cognitive and Neurosensorial Impairment

The research exploring Elistin in the context of age-related cognitive issues, which includes difficulties with concentration and memory loss, primarily involves older randomized controlled trials (RCTs) and subsequent systematic reviews. These studies was evaluated in older adults with heterogeneous symptoms of mild to moderate cognitive impairment, in patients where symptoms were associated with chronic cerebrovascular disorders. Research explored the measurement of outcomes related to daily functioning or activity level, using global assessment scales, and also studied measures of symptoms like confusion, withdrawal, and attention span.

Studies monitored how symptoms presented in the observed populations over short- to intermediate-term follow-up periods. Regulatory assessments noted that research highlights changes measured during the study period, but that the available data described patterns related to a small measured effect on overall global functional status. Certainty remains low regarding the clinical relevance of the small changes observed, as the trials relied on subjective assessment scores.


Evidence for Ancillary Use in Specific Vascular Contexts

Elistin was also evaluated in a limited body of research exploring symptoms related to peripheral vascular disturbances and certain neurosensorial issues, such as specific visual deficits presumed to be of vascular origin. This research primarily consisted of uncontrolled or poorly designed clinical studies. The studies examined measures related to peripheral circulation symptoms (like pain during walking) and subjective assessments of visual disturbances.

Official regulatory reviews have concluded that these studies suffered from substantial methodological deficiencies, including a lack of well-defined primary efficacy endpoints and insufficient duration for observing slowly progressing conditions. Regulatory bodies noted that the quality of evidence in this area provides limited certainty regarding the research findings.


Research Gaps and Areas of Uncertainty

The research on Elistin is characterized by several documented limitations. Evidence quality varies across studies, with many of the primary trials being older and subject to methodological limitations such as modest sample sizes. Regulator evaluations point out that the findings were mixed and inconsistent across different trials. Furthermore, long-term effects are not fully established, as the follow-up durations were limited in most original trials.

Frequently Asked Questions (FAQ)

Common questions about Elistin (FAQ)

Q: Are there any common foods or drinks to avoid while using Elistin?

A: Official documents for Elistin focus primarily on drug-drug interactions. Although specific common foods are not usually listed, regulatory sources warn against taking Elistin with medications that are CYP3A4 inhibitors. These inhibitors can potentially increase the level of Elistin in the body, raising the risk of adverse effects. Patients are generally advised to discuss all co-administered products, including supplements and dietary components, with a healthcare provider.

Q: Do the side effects of Elistin usually go away after a while?

A: Official information indicates that some of the more serious safety concerns associated with Elistin are described as either reversible or transient (temporary). For instance, serious effects like kidney damage (nephrotoxicity) have been described as generally reversible or resolving upon discontinuation of the drug. However, the official documentation does not provide specific timelines for the resolution of all common adverse reactions like dizziness or nausea.

Q: Is Elistin known to interact with common pain relievers like ibuprofen?

A: While the regulatory label may not specifically name every pain reliever, official warnings caution against using Elistin alongside nephrotoxic agents. These are medicines that can cause kidney damage. Since some common over-the-counter pain relievers, such as NSAIDs (like ibuprofen), fall into this category, this combination may increase the risk of toxicity and is a combination that requires careful assessment by a healthcare provider.

Q: Is it normal to feel [general, non-specific symptom] when starting Elistin?

A: According to the official product information, common adverse reactions reported in clinical trials include symptoms such as dizziness, headache, nausea, and gastrointestinal upset. Because the drug affects the central nervous system and circulation, these symptoms may be experienced, particularly when starting treatment. Patients who experience side effects are encouraged to discuss them with their healthcare provider.

Q: What does 'contraindication' mean in the context of Elistin?

A: A contraindication is an official term used in regulatory documents to describe a condition or circumstance where the use of a medicine would be improper or potentially harmful. For Elistin, contraindications include a severe hypersensitivity reaction (a serious allergy) to the drug or the presence of severe hepatic impairment (serious liver damage).

Q: What does 'mechanism of action' mean for Elistin?

A: The mechanism of action is simply the way the drug works inside the body. Official documentation explains that Elistin acts on certain receptors (alpha-adrenoceptors) to help regulate blood flow, especially in the brain. It is also known to influence brain chemicals like dopamine and serotonin to modulate how brain cells use oxygen and glucose.

Q: What happens if I take more than the recommended dose?

A: Taking more than the recommended amount of Elistin can lead to an overdose, potentially causing symptoms of acute ergotism. This can include severe symptoms like persistent nausea and vomiting, confusion, numbness, and tingling of the extremities. Regulatory documents emphasize that suspected overdose requires prompt medical attention.

Q: Does Elistin have a known 'weaning off' period?

A: While regulatory labels do not typically provide a detailed schedule for stopping the drug, Elistin is a CNS-active compound and is approved for long-term management. Clinical guidance for drugs of this type often suggests gradual discontinuation to avoid the return or worsening of symptoms. Discontinuation of Elistin should be done under the guidance of a healthcare professional.

Q: Can Elistin be taken by people who have high blood pressure?

A: According to the official prescribing information, Elistin is contraindicated (should not be used) in patients with specific severe cardiovascular conditions. This includes individuals with uncontrolled hypertension (very high blood pressure) or certain types of ischemic heart disease. Eligibility is determined by a comprehensive assessment by a healthcare provider.

Q: What happens if I stop taking Elistin suddenly?

A: The official documentation does not outline a specific withdrawal syndrome for Elistin. However, due to its action on the central nervous system, abruptly stopping treatment may cause the worsening or return of the underlying symptoms the drug was prescribed to manage. It is generally advised that changes to the medication schedule should be made under the guidance of a healthcare professional.

Q: Can Elistin affect my sleep schedule or energy levels?

A: The list of adverse reactions reported for Elistin includes some symptoms of neurotoxicity (nerve-related side effects), such as dizziness and vertigo. While insomnia (difficulty sleeping) is not listed as a common effect, any neurological changes could potentially affect your normal sleep patterns or alertness.

Q: Is Elistin considered a controlled substance?

A: Elistin (Dihydroergotoxine Mesylate) is a prescription-only medication. However, regulatory agencies such as the U.S. Drug Enforcement Administration (DEA) have not classified it as a controlled substance (e.g., Schedule I-V), indicating that it does not carry the same risk of abuse or dependence.

Q: Can people with a history of heart issues use Elistin?

A: Official regulatory documents indicate that Elistin is contraindicated in patients with a history of specific serious cardiovascular issues. This includes conditions like ischemic heart disease (heart problems due to blocked arteries) and issues related to coronary artery vasospasm. A thorough patient assessment is required before use.

Q: Is Elistin habit-forming or addictive?

A: Regulatory bodies have not categorized Elistin as a controlled substance, and the official label does not include specific warnings regarding addiction or habit formation. This classification indicates that the risk of misuse or dependency is generally considered low.

Q: Can Elistin cause weight changes?

A: Official regulatory documents and clinical trial data for Elistin do not generally list weight changes as one of the common or serious adverse reactions. Side effects are primarily centered on neurological, gastrointestinal, and systemic toxicity effects.

Q: What is the shelf life or expiry information for Elistin?

A: The official shelf life for Elistin is determined by the manufacturer and approved by regulatory authorities based on stability testing. This information, along with the specific expiration date for your product, is printed on the container and found in the full official product information.

Q: Can Elistin be taken at any time of day?

A: The administration section states that Elistin can be taken once daily (qd) or in three divided doses (tid), and can be taken with or without food. Official documentation does not specify a mandatory time of day (such as morning or night) for administration.

How should Elistin be stored and disposed of?

How to Store and Dispose of Elistin

Official regulatory documents define strict storage and disposal requirements for Elistin (Dihydroergotoxine Mesylate).


Storage Conditions

Requirement Specific Instruction
Temperature Store at room temperature, typically 20 C to 25 C. Extreme temperatures must be avoided to maintain stability.
Protection Keep the medication protected from direct sunlight and moisture in a cool, dry, and well-ventilated place.
Container The product must be stored in its original container, which must be tightly closed.

Handling and Disposal

Elistin must be stored out of the sight and reach of children as a mandatory safety measure.

Expired or unused Elistin must not be discarded in household trash or poured down sinks/toilets. Disposal must be managed by an appropriate treatment and disposal facility in accordance with local regulations. Guidance on safe disposal methods should be obtained from a pharmacist or healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Elistin found in:

A-Z Index: